The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of an oral study drug for specific types of breast cancer. This study will look at the effects of taking the study drug with and without a high-fat meal.
Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million people impacted annually. Metastatic breast cancer, the most advanced stage of breast cancer in which the cancer has spread to other parts of the body (i.e., organs, bones), remains an incurable disease.
We are committed to supporting patients by developing innovative medicines that have the potential to help people with various types of breast cancer. Learn how you can help patients as a healthy volunteer below.
Who may participate
Clinical trials are an essential part of finding new and better ways to treat or manage diseases, and they’re only possible because of participants.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**female participants must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18+ years
Sex
All sexes**
Referral bonus
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 21 overnights. The morning after you arrive, you will receive a single dose of the study drug. About 2 weeks later, you will receive another single dose of the study drug. Both doses will be given as a tablet to swallow whole. One of the doses will be given without breakfast, and one will be after a high-fat breakfast.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
This study requires you to stay at the PCRU for the entire duration of each inpatient stay unless you choose to withdraw. You can learn more about what to expect during your participation by browsing our FAQ section.
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
Required overnight stays
21 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 44 days
Compensation
Up to $9,550 upon completion of the study
We've updated the PCRU Loyalty Program!
We refreshed our Participant Loyalty Program with all-new unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.